ACT-1 PEPTIDE
drug drugOn this page
Also known as Acti peptideGranexinGranexin peptidePeptide 328967
Summary
Act-1 Peptide (CHEMBL4297964) is a phase-3 clinical-stage protein; indicated across 2 conditions.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 2 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297964 |
| Name | ACT-1 PEPTIDE |
| Type | Protein |
| Max phase | 3 |
Also known as: Act-1 peptide, Acti peptide, Granexin, Granexin peptide, Peptide 328967, ACT-1 PEPTIDE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02652572 | PHASE1 | COMPLETED | Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.